Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
33
MEIP Quote, Financials, Valuation and Earnings
Last price:
$2.38
Seasonality move
:
-3.18%
Day range:
$2.30 - $2.60
52-week range:
$2.30 - $6.39
Dividend yield:
0%
P/E ratio:
1.16x
P/S ratio:
0.15x
P/B ratio:
0.63x
Volume:
294.2K
Avg. volume:
32.4K
1-year change:
-62.18%
Market cap:
$15.7M
Revenue:
$65.3M
EPS (TTM):
-$6.99
Analysts' Opinion
-
Consensus RatingMEI Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, MEI Pharma has an estimated upside of 747.46% from its current price of $2.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.36.
Fair Value
-
According to the consensus of 0 analysts, MEI Pharma has 747.46% upside to fair value with a price target of -- per share.
MEIP vs. S&P 500
-
Over the past 5 trading days, MEI Pharma has underperformed the S&P 500 by -10.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MEI Pharma does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MEI Pharma has grown year-over-year revenues for 1 quarter straight. In the most recent quarter MEI Pharma reported revenues of --.
Earnings Growth
-
MEI Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MEI Pharma reported earnings per share of -$1.20.
Enterprise value:
-11.2M
EV / Invested capital:
--
Price / LTM sales:
0.15x
EV / EBIT:
-0.69x
EV / Revenue:
-0.11x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-0.68x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $41.7M | $105.4M | -- | $65.3M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$73.6M | $36.7M | -$38.2M | $55.3M | -$8.4M | |
| EBITDA | -$73.3M | $37.1M | -$37.5M | $55.4M | -$8M | |
| Diluted EPS | -$9.04 | $6.17 | -$6.99 | $8.46 | -$1.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $203.9M | $167.4M | $148.9M | $88.4M | $27.7M | |
| Total Assets | $214M | $176.4M | $163.6M | $101.3M | $27.8M | |
| Current Liabilities | $31.5M | $30.4M | $23.4M | $8.6M | $2.9M | |
| Total Liabilities | $131.7M | $144.5M | $126.3M | $19.9M | $2.9M | |
| Total Equity | $82.3M | $31.8M | $37.3M | $81.4M | $24.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$55.8M | -$56.2M | -$43.4M | -$18.5M | -$11.5M | |
| Cash From Investing | $5.6M | $44.9M | $58.9M | $5M | $14.7M | |
| Cash From Financing | $49.2M | -- | -- | -- | -- | |
| Free Cash Flow | -$56.3M | -$56.2M | -$43.4M | -$18.5M | -$11.5M | |
MEIP
Sector
Market Cap
$15.7M
$43.9M
Price % of 52-Week High
36.94%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-62.18%
-29.11%
Beta (5-Year)
0.790
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.55
200-day SMA
Sell
Level
$3.09
Bollinger Bands (100)
Sell
Level
2.7 - 3.18
Chaikin Money Flow
Sell
Level
-163.3M
20-day SMA
Sell
Level
$2.68
Relative Strength Index (RSI14)
Sell
Level
25.75
ADX Line
Sell
Level
12.55
Williams %R
Buy
Level
-89.8115
50-day SMA
Sell
Level
$2.82
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
52.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.1963)
Buy
CA Score
(Annual)
Level (0.6015)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-6.8897)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Stock Forecast FAQ
In the current month, MEIP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MEIP average analyst price target in the past 3 months is --.
-
Where Will MEI Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that MEI Pharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About MEI Pharma?
Analysts are divided on their view about MEI Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MEI Pharma is a Sell and believe this share price will drop from its current level to --.
-
What Is MEI Pharma's Price Target?
The price target for MEI Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MEIP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MEI Pharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MEIP?
You can purchase shares of MEI Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MEI Pharma shares.
-
What Is The MEI Pharma Share Price Today?
MEI Pharma was last trading at $2.38 per share. This represents the most recent stock quote for MEI Pharma. Yesterday, MEI Pharma closed at $2.36 per share.
-
How To Buy MEI Pharma Stock Online?
In order to purchase MEI Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
